Asia-Pacific Blood Plasma and Plasma Derived Medicinal Products Market Size, Trends, Growth Report 2032

Asia Pacific Blood Plasma And Plasma Derived Medicinal Products Market

Market Size in USD Billion

CAGR : 8.73 %

Bar chart comparing the Asia Pacific Blood Plasma And Plasma Derived Medicinal Products Market size in 2024 - 11.61 and 2032 - 5.96, highlighting the projected market growth.

USD 11.61 Billion USD 5.96 Billion 2024 2032

Forecast Period	2025 –2032
Market Size (Base Year)	USD 11.61 Billion
Market Size (Forecast Year)	USD 5.96 Billion
CAGR	8.73 %
Major Markets Players	CSL Takeda Pharmaceutical Company Limited Grifols S.A. Octapharma AG

Asia-Pacific Blood Plasma & Plasma Derived Medicinal Products Market Segmentation, By Product (Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins), Application (Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications), Processing Technology (Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration), Mode (Modern and Traditional Plasma Fractionation), End-User (Hospitals & Clinics, Research Labs, Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributors, and Others) - Industry Trends and Forecast to 2032

Blood Plasma and Plasma Derived Medicinal Products Market Size

The Asia-Pacific blood plasma & plasma derived medicinal products market was valued at USD 5.96 billion in 2024 and is expected to reach USD 11.61 billion by 2032 at a CAGR of 8.73%, during the forecast period
The market growth is largely fueled by the rising prevalence of rare and chronic diseases
Furthermore, blood plasma & plasma derived medicinal products technological advancements in plasma fractionation. These converging factors are accelerating the uptake of blood plasma & plasma derived medicinal products solutions, thereby significantly boosting the industry's growth

Blood Plasma & Plasma Derived Medicinal Products Market Analysis

The market is expanding due to increased demand for plasma-derived therapies in treating conditions like hemophilia, immunodeficiency disorders, and autoimmune diseases, supported by rising awareness and advancements in transfusion medicine
Technological advancements in blood collection, fractionation, and cold chain logistics are enhancing product quality and shelf life, encouraging wider adoption across hospitals, trauma centers, and diagnostic laboratories in Asia-Pacific
China is expected to dominate the blood plasma & plasma derived medicinal products market with 24.89% share in 2025 due to improved healthcare infrastructure, rising demand for plasma therapies, increased government support, and growing prevalence of chronic and infectious diseases
China is expected to be the fastest growing region in the market due to increasing healthcare investments, rising prevalence of chronic and infectious diseases, improved diagnostic facilities, growing awareness about blood safety, and government initiatives to boost plasma therapy accessibility and infrastructure
The immunoglobulins segment is expected to dominate the market with a 41.42% share in 2025 due to rising demand for targeted therapies, improved purification technologies, and increasing prevalence of immune-related disorders

Report Scope and Blood Plasma & Plasma Derived Medicinal Products Market Segmentation

Attributes	Blood Plasma & Plasma Derived Medicinal Products Key Market Insights
Segments Covered	By Product: Immunoglobulins, Coagulation Factors (For Bleeding Disorders), Albumin (Plasma Volume Expander), Protease Inhibitors (For Genetic Deficiencies), Monoclonal Antibodies (Derived From Plasma Cells), and Other Plasma Derived Proteins By Application: Immunology, Hematology, Critical Care, Neurology, Pulmonology, Haemato-Oncology, Rheumatology, and Other Applications By Processing Technology Ion Exchange Chromatography, Affinity Chromatography, Cryoprecipitation, Ultrafiltration, and Microfiltration By Mode Modern and Traditional Plasma Fractionation By End-User: Hospitals & Clinics, Research Labs, Academic Institutes, and Others By Distribution Channel: Direct Tender, Third Party Distributors, and Others
Countries Covered	China Japan South Korea Australia India Malaysia Thailand Singapore Philippines Indonesia New Zealand Vietnam Taiwan Rest of Asia-Pacific
Key Market Players	CSL (Australia) Takeda Pharmaceutical Company Limited (Japan) Grifols, S.A. (Spain) Octapharma AG (Switzerland) Kedrion (Italy) Aegros (Australia) Bharat Serums (India) Biotest AG (Germany) Fresenius Kabi AG (Germany) GC Biopharma corporate (South Korea) ICHOR (India) Intas Pharmaceuticals Ltd. (India) Kamada Pharmaceuticals (Israel) KM Biologics (Japan) PlasmaGen BioSciences Pvt. Ltd. (India) Proliant Health & Biologicals (U.S.) Promea (India) Reliance Life Sciences (India) Sichuan Yuanda Shyuang Pharmaceutical Co., Ltd. (China) SK Plasma (South Korea) Synthaverse S. A. (Poland) Taibang Bio Group Co., Ltd (China) VIRCHOW BIOTECH (India)
Market Opportunities	Advancements in plasma processing technologies to enhance yield and reduce costs Reimbursement frameworks and increased governmental focus on rare disease treatment
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Blood Plasma & Plasma Derived Medicinal Products Market Trends

“Rising Prevalence of Rare and Chronic Diseases”

A major driving force behind the blood plasma & plasma derived medicinal products market is the increasing prevalence of rare and chronic diseases in Asia-Pacific, fueled by advancements in diagnostic technologies and heightened awareness among healthcare providers and patients
For instance, in April 2025, CDC data revealed that 76.4% of U.S. adults had at least one chronic condition, and 51.4% had multiple conditions. This rising trend—also observed among younger adults—has intensified the demand for lifelong care, particularly for conditions like hemophilia, primary immunodeficiency diseases, and von Willebrand disease
Plasma-derived therapies such as immunoglobulins, coagulation factors, and albumin are critical for managing these lifelong conditions. Patients with Primary Immunodeficiency rely on IVIG for immune support, while hemophilia patients require regular clotting factor infusions to prevent bleeding episodes
The global aging population further drives this trend, with older adults increasingly affected by conditions like liver cirrhosis, multiple myeloma, and inflammatory diseases, all of which necessitate plasma-derived interventions
In March 2025, research published in PMC highlighted the immense global burden of rare diseases, especially among pediatric populations. Despite progress in genomic medicine and orphan drug development, delays in diagnosis and limited treatment options persist, underscoring the need for multidisciplinary and sustained care.
The growing demand for safe, effective, and high-quality plasma-derived therapies is a pivotal factor driving the blood plasma & plasma derived medicinal products market, as these products play a crucial role in managing lifelong diseases and addressing unmet medical needs in Asia-Pacific

Blood Plasma & Plasma Derived Medicinal Products Market Dynamics

Driver

“Expanding Geriatric Population”

The increasing demand for Blood Plasma & Plasma Derived Medical Products is significantly driven by the aging global population, which is more prone to chronic and degenerative conditions such as immune system disorders, neurological diseases, liver complications, and blood-related issues that require plasma-based therapies including immunoglobulins, albumin, and clotting factors
For instance, in March 2025, research featured in PMC analyzing US National Inpatient Sample (NIS) data from 2010 to 2024 revealed that the rapidly growing elderly population has led to a substantial rise in hospital admissions, longer hospital stays, and higher readmission rates. This trend, largely driven by chronic illnesses and multimorbidity, highlights the escalating strain on healthcare systems and the corresponding demand for plasma-derived treatments
With advancing age, the immune system weakens, increasing susceptibility to infections and autoimmune disorders. Immunoglobulin therapies are frequently used in managing conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), while albumin is vital in managing fluid balance during surgical procedures and critical care in elderly patients
Countries like Japan, Germany, Italy, and the U.S., which have high proportions of older adults, are witnessing a sustained rise in the consumption of PDMPs. This demographic trend places immense pressure on national healthcare systems to ensure uninterrupted supply chains and adequate plasma collection
The projected increase in the global population aged 60 and above—from 1.1 billion in 2023 to 2.1 billion by 2050, as per WHO estimates—further emphasizes the crucial role of geriatric care. This demographic shift not only amplifies the need for long-term therapeutic support but also positions the elderly population as a key, enduring market segment for PDMPs in Asia-Pacific

Restraint/Challenge

“High Cost and Complex Manufacturing Process”

The high cost and complexity associated with the manufacturing of Blood Plasma & Plasma Derived Medicinal Products present a significant barrier to market expansion. The process requires stringent plasma collection protocols, extensive pathogen screening, and multi-step fractionation under sterile, GMP-compliant environments—making production highly resource-intensive and time-consuming
For instance, a detailed analysis by Aykon Biosciences emphasized that manufacturing complex biologics such as plasma-derived therapies faces rising cost pressures due to expensive raw materials, skilled labor requirements, and increasingly strict regulatory compliance demands. The shift toward specialized and personalized therapies further elevates costs, necessitating advanced technologies and rigorous quality assurance systems
Additionally, the manufacturing cycle for PDMPs can extend up to 12 months, requiring cold-chain logistics for storage and transportation throughout the process. These factors significantly increase capital and operational expenditures, limiting scalability and deterring smaller players and developing economies from participating effectively in the market
The cost-intensive nature of production also contributes to high final product prices, which reduces accessibility and affordability—especially in low- and middle-income countries where healthcare budgets are constrained. This financial burden poses challenges in meeting growing global demand, thereby restraining broader adoption of PDMPs worldwide
While ongoing technological innovation may gradually improve cost-efficiency, the current high production and processing costs remain a central restraint. Addressing these challenges through improved manufacturing technologies, expanded donor infrastructure, and supportive public health funding will be crucial for unlocking wider market access and equitable therapeutic coverage

Blood Plasma & Plasma Derived Medicinal Products Market Scope

The market is segmented on the basis of product, application, processing technology, mode, end user, and distribution channel.

By Product

On the basis of product, the market is segmented into immunoglobulins, coagulation factors (for bleeding disorders), albumin (plasma volume expander), protease inhibitors (for genetic deficiencies), monoclonal antibodies (derived from plasma cells), and other plasma derived proteins. In 2025, the immunoglobulins segment is expected to dominate the market with a market share of 41.42% in 2025, driven by its rising immunodeficiency diagnoses, autoimmune diseases, and increasing intravenous immunoglobulin (IVIG) use.

The coagulation factors (for bleeding disorders) segment is anticipated to witness the fastest growth rate of 8.94% from 2025 to 2032, fueled by rising hemophilia cases, improved diagnostic access, government support, and expanding use of recombinant and plasma-derived therapies.

By Application

On the basis of application, the market is segmented into immunology, hematology, critical care, neurology, pulmonology, haemato-oncology, rheumatology, and other applications. The immunology segment held the largest market revenue share in 2025, driven by its widespread use in treating primary immunodeficiencies, autoimmune disorders, and rising global demand for intravenous immunoglobulin (IVIG).

The immunology segment is expected to witness the fastest CAGR from 2025 to 2032, driven by increasing prevalence of autoimmune diseases, rising aging population, and expanding clinical applications of immunoglobulin therapies.

By Processing Technology

On the basis of processing technology, the market is segmented into ion exchange chromatography, affinity chromatography, cryoprecipitation, ultrafiltration, and microfiltration. The ion exchange chromatography segment held the largest market revenue share in 2025, driven by high efficiency, scalability, and effectiveness in purifying plasma proteins like immunoglobulins, albumin, and coagulation factors.

The affinity chromatography segment is expected to witness the fastest CAGR from 2025 to 2032, favored for its high specificity, ability to isolate target proteins, and growing adoption in advanced biologics purification.

By Mode

On the basis of mode, the market is segmented into modern and traditional plasma fractionation. The modern segment accounted for the largest market revenue share in 2025, driven advanced processing technologies, higher product purity, improved safety profiles, and increased adoption of recombinant and high-yield plasma-derived therapies.

The modern segment is expected to witness the fastest CAGR from 2025 to 2032, driven innovation in purification techniques, rising demand for safer biologics, and growing investments in next-generation plasma processing technologies.

By End User

On the basis of end user, the market is segmented into hospitals & clinics, research labs, academic institutes, and others. The hospitals & clinics segment accounted for the largest market revenue share in 2025, driven by its high patient volume, availability of specialized care, increasing chronic disease treatments, and access to advanced plasma-derived therapies.

The hospitals & clinics segment is also expected to witness the fastest CAGR from 2025 to 2032, propelled by expanding healthcare infrastructure, rising inpatient admissions, and growing reliance on plasma therapies for complex conditions.

By Distribution Channel

On the basis of distribution channel, the market is segmented into direct tender, third party distributors, and others. The direct tender segment accounted for the largest market revenue share in 2025, driven by the bulk purchasing by government bodies, cost-efficiency, assured supply chains, and increasing public sector investments in plasma-derived medicinal products.

The direct tender segment is also expected to witness the fastest CAGR from 2025 to 2032, propelled by expanding government healthcare programs, centralized procurement policies, and rising demand for cost-effective, large-scale plasma therapy distribution.

Blood Plasma & Plasma Derived Medicinal Products Market Regional Analysis

China dominates the blood plasma & plasma derived medical products market with the largest revenue share of 24.89% and is projected to grow at the fastest CAGR of 9.95% in 2025, driven by advanced healthcare infrastructure, increased diagnosis rates of rare and chronic diseases, and high per capita healthcare expenditure
The country’s strong regulatory framework, robust reimbursement systems, and presence of major market players such as Grifols, CSL Behring, and Takeda contribute to Asia-Pacific leadership in plasma collection and therapy distribution
Major economies such as the China, Japan, and India are investing heavily in biopharmaceutical R&D, expanding plasma collection networks, and improving access to plasma-derived therapies for immunology, hematology, and neurology

Japan Blood Plasma & Plasma Derived Medicinal Products Market Insight

The Japan is projected to witness strong growth from 2025 to 2032 in the Asia-Pacific region, attributed to its well-established healthcare ecosystem, growing patient pool for rare and chronic conditions, and robust government initiatives promoting plasma donation. The country's large number of plasma collection centers and accelerated approvals for PDMPs enhance treatment accessibility and drive market expansion.

South Korea Blood Plasma & Plasma Derived Medicinal Products Market Insight

South Korea is expected to register a significant CAGR in the region from 2025 to 2032, driven by its universal healthcare system, rising awareness of rare disorders, and government investments in expanding domestic plasma collection capabilities. Strategic partnerships and advancements in biologics manufacturing are strengthening Canada’s footprint in the PDMPs landscape.

Blood Plasma & Plasma Derived Medicinal Products Market Share

The blood plasma & plasma derived medicinal products industry is primarily led by well-established companies, including:

CSL (Australia)
Takeda Pharmaceutical Company Limited (Japan)
Grifols, S.A. (Spain)
Octapharma AG (Switzerland)
Kedrion (Italy)
Aegros (Australia)
Bharat Serums (India)
Biotest AG (Germany)
Fresenius Kabi AG (Germany)
GC Biopharma corporate (South Korea)
ICHOR (India)
Intas Pharmaceuticals Ltd. (India)
Kamada Pharmaceuticals (Israel)
KM Biologics (Japan)
PlasmaGen BioSciences Pvt. Ltd. (India)
Proliant Health & Biologicals (U.S.)
Promea (India)
Reliance Life Sciences (India)
Sichuan Yuanda Shyuang Pharmaceutical Co., Ltd. (China)
SK Plasma (South Korea)
Synthaverse S. A. (Poland)
Taibang Bio Group Co., Ltd (China)
VIRCHOW BIOTECH (India)

Latest Developments in Blood Plasma & Plasma Derived Medicinal Products Market

In November 2024, CSL Plasma expanded its adoption of the advanced Rika Plasma Donation System across six U.S. donation centers near Denver, Colorado. These new devices, developed jointly with Terumo Blood & Cell Technologies, cut collection times by ~30% while improving donor comfort, safety, and efficiency
In December 2022, CSL inaugurated its new Broadmeadows Plasma Fractionation Facility in Victoria, Australia—the largest plasma grain-processing site in the Southern Hemisphere. With capacity to handle 9.2 million plasma-equivalent liters annually, this USD 900 million facility supports the global demand for plasma-based therapies that treat immunodeficiencies, neurological disorders, and critical conditions like transplants and burns
In June 2024, Takeda announced a USD 30 million expansion of its Los Angeles plasma‑fractionation facility, its global leader per capacity. This upgrade is expected to add up to 2 million liters/year of production volume, helping to meet rising global demand for plasma‑derived therapies used in treating immunodeficiencies and bleeding disorders
In 2023, Takeda committed approximately USD 765 million to build a new plasma‑derived therapy manufacturing plant in Osaka, Japan—nearly quintupling capacity at its existing Narita site. This facility is projected to be fully operational by 2030 and will serve both the Japanese and global markets
In March 2025, Grifols partnered with Inpeco to integrate advanced automation robotics (FlexLab X), diagnostics, and reagents, creating “labs of the future” for high‑throughput, safer, traceable blood and plasma testing in transfusion Medicine labs analyze biological samples to diagnose, monitor, and research diseases

SKU-74264

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE ANALYSIS

4.1.1 POLITICAL FACTORS

4.1.2 ECONOMIC FACTORS

4.1.3 SOCIAL FACTORS

4.1.4 TECHNOLOGICAL FACTORS

4.1.5 ENVIRONMENTAL FACTORS

4.1.6 LEGAL FACTORS

4.2 PORTER’S FIVE FORCES

4.2.1 THREAT OF NEW ENTRANTS

4.2.2 BARGAINING POWER OF SUPPLIERS

4.2.3 BARGAINING POWER OF BUYERS

4.2.4 THREAT OF SUBSTITUTES

4.2.5 INDUSTRY RIVALRY

4.3 SUPPLY CHAIN IMPACT ON THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET

4.3.1 OVERVIEW

4.3.2 RAW MATERIAL AVAILABILITY

4.3.3 MANUFACTURING CAPACITY

4.3.4 LOGISTICS AND LAST-MILE HURDLES

4.3.5 PRICING MODELS AND MARKET POSITIONING

4.4 INNOVATION STRATEGIES

4.4.1 KEY INNOVATION STRATEGIES

4.4.2 EMERGING DELIVERY TECHNIQUES

4.4.3 STRATEGIC IMPLICATIONS

4.4.4 CONCLUSION

4.5 RISK AND MITIGATION

4.6 VENDOR SELECTION DYNAMICS

4.6.1 PRODUCT QUALITY AND REGULATORY COMPLIANCE

4.6.2 SUPPLY CHAIN CAPABILITIES AND RELIABILITY

4.6.3 CLINICAL EFFICACY AND INNOVATION

4.6.4 COST COMPETITIVENESS AND REIMBURSEMENT COMPATIBILITY

4.6.5 LOCAL MARKET PRESENCE AND SUPPORT INFRASTRUCTURE

4.6.6 ETHICAL SOURCING, ESG COMPLIANCE, AND TRANSPARENCY

4.6.7 CONCLUSION

4.7 TARIFFS AND THEIR IMPACT ON MARKET

4.7.1 CURRENT TARIFF RATES IN TOP-5 COUNTRY MARKETS

4.7.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE

4.7.3 VENDOR SELECTION CRITERIA DYNAMICS

4.7.4 IMPACT ON SUPPLY CHAIN

4.7.5 IMPACT ON PRICES

4.7.6 REGULATORY INCLINATION

4.7.6.1 GCC TRADE ALIGNMENT & FTAS

4.7.6.2 SPECIAL ZONES AND RE-EXPORT MODELS

4.7.6.3 LOCAL SUBSIDY & POLICY RESPONSE

4.7.6.4 DOMESTIC COURSE OF CORRECTION

5 REGULATION COVERAGE

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING PREVALENCE OF RARE AND CHRONIC DISEASES

6.1.2 EXPANDING GERIATRIC POPULATION

6.1.3 TECHNOLOGICAL ADVANCEMENTS IN PLASMA FRACTIONATION

6.1.4 GOVERNMENT AND INSTITUTIONAL SUPPORT

6.2 RESTRAINTS

6.2.1 HIGH COST AND COMPLEX MANUFACTURING PROCESS

6.2.2 LACK OF PLASMA SUPPLY AND DONOR

6.3 OPPORTUNITIES

6.3.1 ADVANCEMENTS IN PLASMA PROCESSING TECHNOLOGIES TO ENHANCE YIELD AND REDUCE COSTS

6.3.2 REIMBURSEMENT FRAMEWORKS AND INCREASED GOVERNMENTAL FOCUS ON RARE DISEASE TREATMENT

6.3.3 STRATEGIC ALLIANCES, MERGERS, AND ACQUISITIONS TO STRENGTHEN ASIA-PACIFIC MARKET PENETRATION

6.4 CHALLENGES

6.4.1 COMPETITIVE PRESSURE FROM RECOMBINANT AND ALTERNATIVE BIOLOGICAL THERAPIES

6.4.2 INFRASTRUCTURE LIMITATIONS IN COLD CHAIN LOGISTICS IMPACTING PRODUCT DISTRIBUTION

7 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT

7.1 OVERVIEW

7.2 IMMUNOGLOBULINS

7.3 COAGULATION FACTORS (FOR BLEEDING DISORDERS)

7.4 ALBUMIN (PLASMA VOLUME EXPANDER)

7.5 PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)

7.6 MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS)

7.7 OTHER PLASMA DERIVED PROTEINS

8 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION

8.1 OVERVIEW

8.2 IMMUNOLOGY

8.3 HEMATOLOGY

8.4 CRITICAL CARE

8.5 NEUROLOGY

8.6 PULMONOLOGY

8.7 HAEMATO-ONCOLOGY

8.8 RHEUMATOLOGY

8.9 OTHER APPLICATIONS

9 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 ION EXCHANGE CHROMATOGRAPHY

9.3 AFFINITY CHROMATOGRAPHY

9.4 CRYOPRECIPITATION

9.5 ULTRAFILTRATION

9.6 MICROFILTRATION

10 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE

10.1 OVERVIEW

10.2 MODERN

10.3 TRADITIONAL PLASMA FRACTIONATION

11 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS & CLINICS

11.3 RESEARCH LABS

11.4 ACADEMIC INSTITUTES

11.5 OTHERS

12 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDERS

12.3 THIRD PARTY DISTRIBUTORS

12.4 OTHERS

13 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION

13.1 ASIA-PACIFIC

13.1.1 CHINA

13.1.2 JAPAN

13.1.3 SOUTH KOREA

13.1.4 AUSTRALIA

13.1.5 INDIA

13.1.6 MALAYSIA

13.1.7 THAILAND

13.1.8 SINGAPORE

13.1.9 PHILIPPINES

13.1.10 INDONESIA

13.1.11 NEW ZEALAND

13.1.12 VIETNAM

13.1.13 TAIWAN

13.1.14 REST OF ASIA-PACIFIC

14 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 CSL

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 GRIFOLS, S.A.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 OCTAPHARMA AG

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 KEDRION

16.5.1 COMPANY SNAPSHOT

16.5.2 COMPANY SHARE ANALYSIS

16.5.3 PRODUCT PORTFOLIO

16.5.4 RECENT DEVELOPMENT

16.6 ADMA BIOLOGICS, INC

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENT

16.7 AEGROS

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 BHARAT SERUMS

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENT

16.9 BIOTEST AG.

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 FRESENIUS KABI AG

16.10.1 COMPANY SNAPSHOT

16.10.2 PRODUCT PORTFOLIO

16.10.3 RECENT DEVELOPMENT

16.11 GC BIOPHARMA CORPORATE

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 ICHOR

16.12.1 COMPANY SNAPSHOT

16.12.2 PRODUCT PORTFOLIO

16.12.3 RECENT DEVELOPMENT

16.13 INTAS PHARMACEUTICALS LTD.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENT

16.14 KAMADA PHARMACEUTICALS

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENT

16.15 KM BIOLOGICS

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 LFB

16.16.1 COMPANY SNAPSHOT

16.16.2 PRODUCT PORTFOLIO

16.16.3 RECENT DEVELOPMENT

16.17 PLASMAGEN BIOSCIENCES PVT. LTD.

16.17.1 COMPANY SNAPSHOT

16.17.2 PRODUCT PORTFOLIO

16.17.3 RECENT DEVELOPMENTS

16.18 PROLIANT HEALTH & BIOLOGICALS

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENT

16.19 PROMEA

16.19.1 COMPANY SNAPSHOT

16.19.2 PRODUCT PORTFOLIO

16.19.3 RECENT DEVELOPMENT

16.2 RELIANCE LIFE SCIENCES

16.20.1 COMPANY SNAPSHOT

16.20.2 BUSINESS PORTFOLIO

16.20.3 RECENT DEVELOPMENT

16.21 SICHUAN YUANDA SHYUANG PHARMACEUTICAL CO., LTD.

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENT

16.22 SK PLASMA

16.22.1 COMPANY SNAPSHOT

16.22.2 PRODUCT PORTFOLIO

16.22.3 RECENT DEVELOPMENT

16.23 SYNTHAVERSE S. A.

16.23.1 COMPANY SNAPSHOT

16.23.2 REVENUE ANALYSIS

16.23.3 PRODUCT PORTFOLIO

16.23.4 RECENT DEVELOPMENTS

16.24 TAIBANG BIO GROUP CO., LTD

16.24.1 COMPANY SNAPSHOT

16.24.2 PRODUCT PORTFOLIO

16.24.3 RECENT DEVELOPMENT

16.25 VIRCHOW BIOTECH

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

List of Table

TABLE 1 REGULATORY FRAMEWORK AND GUIDELINES

TABLE 2 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 3 ASIA-PACIFIC IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 4 ASIA-PACIFIC IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 5 ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 6 ASIA-PACIFIC INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 7 ASIA-PACIFIC COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 8 ASIA-PACIFIC COAGULATION FACTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 9 ASIA-PACIFIC FACTOR IX IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 10 ASIA-PACIFIC RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 11 ASIA-PACIFIC FACTOR VIII IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 12 ASIA-PACIFIC RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 13 ASIA-PACIFIC FIBRINOGEN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 14 ASIA-PACIFIC PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 15 ASIA-PACIFIC VON WILLEBRAND FACTOR (VWF) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 16 ASIA-PACIFIC FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 17 ASIA-PACIFIC FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 18 IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 19 ASIA-PACIFIC ALBUMIN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 20 ASIA-PACIFIC PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES)IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 21 ASIA-PACIFIC PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 22 ASIA-PACIFIC ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 23 ASIA-PACIFIC C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 24 ASIA-PACIFIC MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS )IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 25 ASIA-PACIFIC MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 26 ASIA-PACIFIC OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 27 ASIA-PACIFIC OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 28 ASIA-PACIFIC ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2025-2032 (USD THOUSAND)

TABLE 29 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2025-2032 (USD THOUSAND)

TABLE 30 ASIA-PACIFIC IMMUNOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 31 ASIA-PACIFIC HEMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 32 ASIA-PACIFIC CRITICAL CARE IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 33 ASIA-PACIFIC NEUROLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 34 ASIA-PACIFIC PULMONOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 35 ASIA-PACIFIC HEMATOLOGY -ONCOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 36 ASIA-PACIFIC RHEUMATOLOGY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 37 ASIA-PACIFIC OTHER APPLICATIONS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 38 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TECHNOLOGY, 2025-2032 (USD THOUSAND)

TABLE 39 ASIA-PACIFIC ION EXCHANGE CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 40 ASIA-PACIFIC AFFINITY CHROMATOGRAPHY IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 41 ASIA-PACIFIC CRYOPRECIPITATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC ULTRAFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC MICROFILTRATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2025-2032 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC MODERN IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC TRADITIONAL PLASMA FRACTIONATION IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2025-2032 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC HOSPITALS & CLINICS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC RESEARCH LABS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC ACADEMIC INSTITUTES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC OTHERS BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC DIRECT TENDERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC THIRD PARTY DISTRIBUTORS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC OTHERS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY REGION, 2025-2032 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 ASIA-PACIFIC RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 ASIA-PACIFIC FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 65 ASIA-PACIFIC RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 66 ASIA-PACIFIC FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 ASIA-PACIFIC PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 ASIA-PACIFIC VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 69 ASIA-PACIFIC FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 ASIA-PACIFIC FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 71 ASIA-PACIFIC ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 72 ASIA-PACIFIC PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 ASIA-PACIFIC ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 ASIA-PACIFIC C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 75 ASIA-PACIFIC MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 76 ASIA-PACIFIC OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 ASIA-PACIFIC ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 79 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 80 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 81 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 82 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 83 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 84 CHINA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 85 CHINA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 CHINA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 CHINA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 88 CHINA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 CHINA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 90 CHINA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 91 CHINA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 CHINA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 93 CHINA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 94 CHINA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 CHINA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 CHINA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 97 CHINA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 98 CHINA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 99 CHINA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 CHINA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 CHINA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 102 CHINA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 103 CHINA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 105 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 106 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 107 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 108 CHINA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 109 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 110 JAPAN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 111 JAPAN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 112 JAPAN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 JAPAN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 JAPAN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 115 JAPAN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 JAPAN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 117 JAPAN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 JAPAN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 JAPAN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 120 JAPAN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 121 JAPAN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 JAPAN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 JAPAN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 124 JAPAN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 JAPAN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 126 JAPAN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 JAPAN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 JAPAN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 129 JAPAN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 130 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 131 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 132 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 133 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 134 JAPAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 135 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 136 SOUTH KOREA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 SOUTH KOREA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 138 SOUTH KOREA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 139 SOUTH KOREA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 SOUTH KOREA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 SOUTH KOREA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 142 SOUTH KOREA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 SOUTH KOREA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 144 SOUTH KOREA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 SOUTH KOREA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 SOUTH KOREA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 147 SOUTH KOREA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 148 SOUTH KOREA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 SOUTH KOREA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 SOUTH KOREA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 151 SOUTH KOREA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 SOUTH KOREA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 153 SOUTH KOREA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 SOUTH KOREA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 SOUTH KOREA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 156 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 157 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 158 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 159 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 160 SOUTH KOREA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 161 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 162 AUSTRALIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 AUSTRALIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 AUSTRALIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 165 AUSTRALIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 166 AUSTRALIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 AUSTRALIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 AUSTRALIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 169 AUSTRALIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 AUSTRALIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 171 AUSTRALIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 AUSTRALIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 AUSTRALIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 174 AUSTRALIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 175 AUSTRALIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 AUSTRALIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 AUSTRALIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 178 AUSTRALIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 AUSTRALIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 180 AUSTRALIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 AUSTRALIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 183 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 184 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 185 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 186 AUSTRALIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 187 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 188 INDIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 189 INDIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 INDIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 INDIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 192 INDIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 193 INDIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 INDIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 INDIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 196 INDIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 INDIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 198 INDIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 199 INDIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 200 INDIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 INDIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 INDIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 203 INDIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 204 INDIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 INDIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 INDIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 207 INDIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 209 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 210 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 211 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 212 INDIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 213 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 214 MALAYSIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 MALAYSIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 216 MALAYSIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 MALAYSIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 218 MALAYSIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 MALAYSIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 MALAYSIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 221 MALAYSIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 222 MALAYSIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 MALAYSIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 224 MALAYSIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 225 MALAYSIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 MALAYSIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 227 MALAYSIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 MALAYSIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 MALAYSIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 230 MALAYSIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 231 MALAYSIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 MALAYSIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 MALAYSIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 234 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 235 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 236 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 237 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 238 MALAYSIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 239 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 240 THAILAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 THAILAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 THAILAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 243 THAILAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 244 THAILAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 245 THAILAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 THAILAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 THAILAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 248 THAILAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 249 THAILAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 THAILAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 THAILAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 252 THAILAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 THAILAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 254 THAILAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 THAILAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 THAILAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 257 THAILAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 258 THAILAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 THAILAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 261 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 262 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 263 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 264 THAILAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 265 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 266 SINGAPORE IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 267 SINGAPORE INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 SINGAPORE INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 SINGAPORE COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 270 SINGAPORE FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 SINGAPORE RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 272 SINGAPORE FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 SINGAPORE RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 SINGAPORE FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 275 SINGAPORE PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 276 SINGAPORE VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 SINGAPORE FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 SINGAPORE FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 279 SINGAPORE ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 SINGAPORE PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 281 SINGAPORE ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 SINGAPORE C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 SINGAPORE MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 284 SINGAPORE OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 285 SINGAPORE ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 287 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 288 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 289 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 290 SINGAPORE BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 291 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 292 PHILIPPINES IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 293 PHILIPPINES INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 294 PHILIPPINES INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 PHILIPPINES COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 PHILIPPINES FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 297 PHILIPPINES RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 PHILIPPINES FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 299 PHILIPPINES RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 PHILIPPINES FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 PHILIPPINES PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 302 PHILIPPINES VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 303 PHILIPPINES FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 PHILIPPINES FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 PHILIPPINES ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 306 PHILIPPINES PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 PHILIPPINES ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 308 PHILIPPINES C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 PHILIPPINES MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 PHILIPPINES OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 311 PHILIPPINES ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 312 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 313 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 314 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 315 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 316 PHILIPPINES BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 317 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 318 INDONESIA IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 319 INDONESIA INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 INDONESIA INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 INDONESIA COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 322 INDONESIA FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 323 INDONESIA RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 INDONESIA FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 INDONESIA RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 326 INDONESIA FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 INDONESIA PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 328 INDONESIA VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 INDONESIA FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 INDONESIA FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 331 INDONESIA ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 332 INDONESIA PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 INDONESIA ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 INDONESIA C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 335 INDONESIA MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 INDONESIA OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 337 INDONESIA ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 339 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 340 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 341 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 342 INDONESIA BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 343 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 344 NEW ZEALAND IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 NEW ZEALAND INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 346 NEW ZEALAND INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 NEW ZEALAND COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 NEW ZEALAND FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 349 NEW ZEALAND RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 350 NEW ZEALAND FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 NEW ZEALAND RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 NEW ZEALAND FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 353 NEW ZEALAND PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 NEW ZEALAND VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 355 NEW ZEALAND FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 NEW ZEALAND FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 NEW ZEALAND ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 358 NEW ZEALAND PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 359 NEW ZEALAND ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 NEW ZEALAND C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 NEW ZEALAND MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 362 NEW ZEALAND OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 NEW ZEALAND ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 364 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 365 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 366 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 367 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 368 NEW ZEALAND BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 369 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 370 VIETNAM IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 VIETNAM INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 VIETNAM INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 373 VIETNAM COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 VIETNAM FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 375 VIETNAM RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 VIETNAM FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 VIETNAM RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 378 VIETNAM FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 379 VIETNAM PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 380 VIETNAM VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 VIETNAM FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 382 VIETNAM FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 VIETNAM ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 384 VIETNAM PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 VIETNAM ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 VIETNAM C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 387 VIETNAM MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 388 VIETNAM OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 VIETNAM ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 391 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 392 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 393 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 394 VIETNAM BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 395 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

TABLE 396 TAIWAN IMMUNOGLOBULINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 397 TAIWAN INTRAVENOUS IMMUNOGLOBULINS (IVIGS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 TAIWAN INTRAMUSCULAR IMMUNOGLOBULINS (IMIG) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 TAIWAN COAGULATION FACTORS (FOR BLEEDING DISORDERS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 400 TAIWAN FACTOR IX PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 TAIWAN RECOMBINANT FACTOR IX (RFIX) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 402 TAIWAN FACTOR VIII PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 TAIWAN RECOMBINANT FACTOR VIII (RFVIII) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 TAIWAN FIBRINOGEN CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 405 TAIWAN PROTHROMBIN COMPLEX CONCENTRATES (PCCS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 406 TAIWAN VON WILLEBRAND FACTOR (VWF) PRODUCTS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 TAIWAN FACTOR XIII CONCENTRATES IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 TAIWAN FACTOR VIIA IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 409 TAIWAN ALBUMIN (PLASMA VOLUME EXPANDER) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 TAIWAN PROTEASE INHIBITORS (FOR GENETIC DEFICIENCIES) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 411 TAIWAN ALPHA 1 ANTITRYPSIN (AAT) (FOR AAT DEFICIENCY) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 TAIWAN C1 ESTERASE INHIBITOR (C1 INH) (FOR HAE) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 413 TAIWAN MONOCLONAL ANTIBODIES (DERIVED FROM PLASMA CELLS) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 414 TAIWAN OTHER PLASMA DERIVED PROTEINS IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 415 TAIWAN ANTITHROMBIN III (AT III) (FOR THROMBOSIS PREVENTION) IN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 417 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PROCESSING TECHNOLOGY, 2018-2032 (USD THOUSAND)

TABLE 418 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY MODE, 2018-2032 (USD THOUSAND)

TABLE 419 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 420 TAIWAN BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)

TABLE 421 REST OF ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT, 2018-2032 (USD THOUSAND)

List of Figure

FIGURE 1 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MULTIVARIATE MODELLING

FIGURE 7 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: SEGMENTATION

FIGURE 12 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET, BY PRODUCT (2024)

FIGURE 13 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: EXECUTIVE SUMMARY

FIGURE 14 STRATEGIC DECISIONS

FIGURE 15 RISING PREVALENCE OF RARE AND CHRONIC DISEASES IS EXPECTED TO DRIVE THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 16 IMMUNOGLOBULINS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET IN THE FORECAST PERIOD OF 2025 & 2032

FIGURE 17 PORTER’S FIVE FORCES

FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES FOR THE ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET

FIGURE 19 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2024

FIGURE 20 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, 2025-2032 (USD THOUSAND)

FIGURE 21 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, CAGR (2025-2032) (2025-2032)

FIGURE 22 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2024

FIGURE 24 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)

FIGURE 25 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, CAGR (2025-2032) (2025-2032)

FIGURE 26 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2024

FIGURE 28 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, 2025-2032 (USD THOUSAND)

FIGURE 29 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, CAGR (2025-2032) (2025-2032)

FIGURE 30 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2024

FIGURE 32 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, 2025-2032 (USD THOUSAND)

FIGURE 33 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, CAGR (2025-2032) (2025-2032)

FIGURE 34 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY MODE, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2024

FIGURE 36 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, 2025-2032 (USD THOUSAND)

FIGURE 37 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, CAGR (2025-2032) (2025-2032)

FIGURE 38 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY END USER, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2024

FIGURE 40 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)

FIGURE 41 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032) (2025-2032)

FIGURE 42 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC BLOOD PLASMA & PLASMA DERIVED MEDICINAL PRODUCTS MARKET: COMPANY SHARE 2024 (%)

View Detailed Information

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

What is the current market size of the Asia-Pacific blood plasma & plasma derived medicinal products market?

The Asia-Pacific blood plasma & plasma derived medicinal products market size was valued at USD 5.96 billion in 2024.

What is the expected growth rate of Asia-Pacific and blood plasma & plasma derived medicinal products market?

The Asia-Pacific blood plasma & plasma derived medicinal products is to grow at a CAGR of 8.73% during the forecast period of 2025 to 2032.

What are the primary segments covered in the Asia-Pacific and blood plasma & plasma derived medicinal products market report?

The blood plasma & plasma derived medicinal products market is segmented into six notable segments based on product, application, processing technology, mode, end user, and distribution channel. On the basis of product, the market is segmented into immunoglobulins, coagulation factors (for bleeding disorders), albumin (plasma volume expander), protease inhibitors (for genetic deficiencies), monoclonal antibodies (derived from plasma cells), and other plasma derived proteins. On the basis of application, the market is segmented into immunology, hematology, critical care, neurology, pulmonology, haemato-oncology, rheumatology, and other applications. On the basis of processing technology, the market is segmented into ion exchange chromatography, affinity chromatography, cryoprecipitation, ultrafiltration, and microfiltration. On the basis of mode, the market is segmented into modern and traditional plasma fractionation. On the basis of end user, the market is segmented into hospitals & clinics, research labs, academic institutes, and others. On the basis of distribution channel, the market is segmented into direct tender, third party distributors, and others.

Who are major players in blood plasma & plasma derived medicinal products market?

Companies such as CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), Octapharma AG (Switzerland), and Kedrion (Italy) are major players in blood plasma & plasma derived medicinal products market.

What are the recent product launches by major companies in the blood plasma & plasma derived medicinal products market?

In June 2024, Plasmagen Biosciences launched Haemocomplettan P (Human Fibrinogen Concentrate) in India. This product, manufactured by CSL Behring, is aimed at addressing massive bleeding during cardiac and liver transplant surgeries and other hemorrhagic conditions, for which Plasmagen is the exclusive distributor in India.

Which countries data is covered in the blood plasma & plasma derived medicinal products market?

The countries covered in the Asia-Pacific blood plasma & plasma derived medicinal products market are China, Japan, South Korea, Australia, India, Malaysia, Thailand, Singapore, Philippines, Indonesia, New Zealand, Vietnam, Taiwan, Rest of Asia-Pacific.

Which country is expected to dominate in the blood plasma & plasma derived medicinal products market?

China is expected to dominate the blood plasma & plasma derived medicinal products market with due to the technological advancements in plasma fractionation.

Which country is expected to witness the highest CAGR in the blood plasma & plasma derived medicinal products market ?

China is expected to be the fastest growing country in the blood plasma & plasma derived medicinal products market due to increasing healthcare investments, rising prevalence of chronic and infectious diseases, growing awareness about plasma therapies, and expanding infrastructure for blood collection, processing, and transfusion services.

Which is the dominating segment in the blood plasma & plasma derived medicinal products market?

The Immunoglobulins segment is expected to dominate the Asia-Pacific and blood plasma & plasma derived medicinal products market in with a share of 41.42% in 2025 due to rising prevalence of immunodeficiency disorders, increasing use in autoimmune and infectious diseases, and expanding access to advanced therapeutic treatments across the region.

What are the key trends in the blood plasma & plasma derived medicinal products market?

The market is witnessing trends like increased demand for plasma-derived therapies, technological advancements in blood fractionation, growing use of recombinant alternatives, rising awareness about blood donations, and government support for advanced healthcare infrastructure, especially in emerging economies.

What are the factors driving the blood plasma & plasma derived medicinal products market growth?

Key growth drivers include rising prevalence of chronic diseases, increasing surgical procedures, growing demand for immunoglobulins and coagulation factors, expansion of healthcare facilities, and favorable government initiatives for blood collection, storage, and transfusion safety across both developed and developing regions.

What are the major challenges in the blood plasma & plasma derived medicinal products market?

Challenges include high costs of blood processing, stringent regulatory frameworks, limited availability of safe donors, risk of transfusion-transmitted infections, and logistical issues in maintaining cold chain storage and distribution, particularly in remote and underdeveloped regions.

Asia-Pacific Blood Plasma and Plasma Derived Medicinal Products Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Circumvent the Tariff challenges with an agile supply chain Consulting

Asia Pacific Blood Plasma And Plasma Derived Medicinal Products Market

CAGR : 8.73 %

Blood Plasma and Plasma Derived Medicinal Products Market Size

Blood Plasma & Plasma Derived Medicinal Products Market Analysis

Blood Plasma & Plasma Derived Medicinal Products Market Trends

Blood Plasma & Plasma Derived Medicinal Products Market Dynamics

Blood Plasma & Plasma Derived Medicinal Products Market Scope

Blood Plasma & Plasma Derived Medicinal Products Market Regional Analysis

Blood Plasma & Plasma Derived Medicinal Products Market Share

Latest Developments in Blood Plasma & Plasma Derived Medicinal Products Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the current market size of the Asia-Pacific blood plasma & plasma derived medicinal products market?

What is the expected growth rate of Asia-Pacific and blood plasma & plasma derived medicinal products market?

What are the primary segments covered in the Asia-Pacific and blood plasma & plasma derived medicinal products market report?

Who are major players in blood plasma & plasma derived medicinal products market?

What are the recent product launches by major companies in the blood plasma & plasma derived medicinal products market?

Which countries data is covered in the blood plasma & plasma derived medicinal products market?

Which country is expected to dominate in the blood plasma & plasma derived medicinal products market?

Which country is expected to witness the highest CAGR in the blood plasma & plasma derived medicinal products market ?

Which is the dominating segment in the blood plasma & plasma derived medicinal products market?

What are the key trends in the blood plasma & plasma derived medicinal products market?

What are the factors driving the blood plasma & plasma derived medicinal products market growth?

What are the major challenges in the blood plasma & plasma derived medicinal products market?

Industry Related Reports

Asia-Pacific Blood Plasma and Plasma Derived Medicinal Products Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Circumvent the Tariff challenges with an agile supply chain Consulting

Asia Pacific Blood Plasma And Plasma Derived Medicinal Products Market

CAGR : 8.73 %

Blood Plasma and Plasma Derived Medicinal Products Market Size

Blood Plasma & Plasma Derived Medicinal Products Market Analysis

Blood Plasma & Plasma Derived Medicinal Products Market Trends

Blood Plasma & Plasma Derived Medicinal Products Market Dynamics

Blood Plasma & Plasma Derived Medicinal Products Market Scope

Blood Plasma & Plasma Derived Medicinal Products Market Regional Analysis

Blood Plasma & Plasma Derived Medicinal Products Market Share

Latest Developments in Blood Plasma & Plasma Derived Medicinal Products Market

Get online access to the report on the World's First Market Intelligence Cloud

Table of Content

List of Table

List of Figure

Research Methodology

Customization Available

Frequently Asked Questions

What is the current market size of the Asia-Pacific blood plasma & plasma derived medicinal products market?

What is the expected growth rate of Asia-Pacific and blood plasma & plasma derived medicinal products market?

What are the primary segments covered in the Asia-Pacific and blood plasma & plasma derived medicinal products market report?

Who are major players in blood plasma & plasma derived medicinal products market?

What are the recent product launches by major companies in the blood plasma & plasma derived medicinal products market?

Which countries data is covered in the blood plasma & plasma derived medicinal products market?

Which country is expected to dominate in the blood plasma & plasma derived medicinal products market?

Which country is expected to witness the highest CAGR in the blood plasma & plasma derived medicinal products market ?

Which is the dominating segment in the blood plasma & plasma derived medicinal products market?

What are the key trends in the blood plasma & plasma derived medicinal products market?

What are the factors driving the blood plasma & plasma derived medicinal products market growth?

What are the major challenges in the blood plasma & plasma derived medicinal products market?

Industry Related Reports

Browse Related Pages

Browse Related Blogs

Browse Related Infographics

Browse Related Press Release

Market Statistics